
Fortress Biotech, Inc.: financial statements
Price
$1.71
November 16, 2026Market cap $54M
What Ploutos Investor adds for Fortress Biotech
Part of Ploutos Investor, €9.99 a month
- The full history: 13 fiscal years, from 2013
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The reported profit is far larger than a business usually earns on its market value, which usually means one-off or accounting gains. We leave out the P/E and the earnings yield.
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
- A figure that did not match the numbers it is built from has been left out.
Financial statements
Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.
Click a line to see it on the chart.
Revenue
-13.5% a year over 2 years
| Line | 2023 | 2024 | 2025 | Average a year |
|---|---|---|---|---|
| Revenue | $85M | $58M | $63M | -13.5% |
| Cost of revenue | $23M | $21M | $21M | -4.4% |
| Gross profit | $62M | $37M | $42M | -17.1% |
| Operating income | -$142M | -$110M | -$70M | |
| Net income | -$61M | -$46M | $6.8M | |
| Earnings per share | -$127.05 | -$2.69 | -$0.07 | |
| Earnings per share, basic | -$127.05 | -$2.69 | -$0.07 | |
| Margins | ||||
| Gross margin | 72.9% | 63.8% | 66.9% | |
| Operating margin | -168.4% | -191.4% | -111.0% | |
| Net margin | -71.7% | -79.8% | 10.8% | |
Financial statements
FBIO's revenue, profits and cash flows from 2013 to 2022, 10 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
By segment
Revenue and operating income by business segment or by product, as the company itself reports them in each year's 10-K. Each year from the latest filing that carries it, so a segment renamed or re-cut shows in its current form.
- Journey
- Avenue Therapeutics Inc
- Checkpoint
- Fortress Biotech Inc
- 2023: Journey $79M, Avenue Therapeutics Inc –, Checkpoint $103.0K, Fortress Biotech Inc $5.2M
- 2024: Journey $56M, Avenue Therapeutics Inc –, Checkpoint $41.0K, Fortress Biotech Inc $1.5M
- 2025: Journey $62M, Avenue Therapeutics Inc $1.4M, Checkpoint –, Fortress Biotech Inc –
| Segment | 2023 | 2024 | 2025 | Share 2025 |
|---|---|---|---|---|
| Journey | $79M | $56M | $62M | 98% |
| Avenue Therapeutics Inc | – | – | $1.4M | 2.2% |
By segment
FBIO's revenue by segment from 2015 to 2022, 8 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
From the XBRL of 12 of the company's annual reports to the SEC (ASC 280). Amounts in dollars.
Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.
Debt and obligations
What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.
The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
Leases
Dec 31, 2025Operating leases
$15M
Finance leases
–
The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing
From the statutory to the effective tax rate, 2025
Dec 31, 2025Statutory rate
21.0%
Effective rate
1.9%
The company paid 1.9% in tax on its profit, 19.1 points below the US federal rate (21.0%). Below, the reasons it gives.
Statutory rate
21.0%
Acquisitions and disposals
-224.8 pts
Difference the filing does not itemize
+205.7 pts
Effective rate
1.9%
One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing
Claims ahead of shareholders
What stands between the business and its shareholders besides the debt, and the financial assets on the other side, from the latest balance sheet.
$17M of other claims rank ahead of the shares, about 32% of the market value.
On the other side, it holds $12M of long-term securities and stakes in other companies, at the value in its accounts, about 22% of the market value.
Ahead of the shares
- at Sep 30, 2026
- $17M
On the other side
- at Sep 30, 2026
- $12M
From the balance sheet of September 30, 2026. The retirement and environmental lines and the pension deficit come from the latest annual report when the quarter's filing does not state them, each with its own date. Market value at the price of November 16, 2026. A line is listed when it is at least 0.5% of the market value. A description of the balance sheet, not a valuation.
Earnings quality
How the reported earnings were made, read from the filings. A description, not a score: our tests found no link between these measures and later share returns.
Receivables and inventory against sales
In the quarter to Sep 30, 2026, sales were +11.2% on the same quarter a year earlier, and receivables +163.5%. Inventory was -34.2%, against +2.2% for the cost of sales.
- Days of sales in receivables rose more than at nine in ten S&P 500 companies.
- a year earlier 96 days
- 228 days
- a year earlier 187 days
- 120 days
Balances at Sep 30, 2026 and Sep 30, 2025, against the sales and cost of sales of the quarter ending on each date; a fourth quarter is the fiscal year less its first nine months. Same quarter against same quarter, so the season is the same.
The earnings per share split is not shown: it needs a profit before tax in both years, since a tax rate on a loss has no meaning as a source.
The allowance for doubtful accounts is not shown: the company does not tag it in its structured filings.
The tax part is not shown: a figure it needs is missing from the company's structured filings.
A reading is called out when it is above the 90th percentile of the same reading across the S&P 500, or, for a fall, below the 10th, as measured on 9 November 2026. Each part uses only the company's own filings.
The full analysis
What do Fortress Biotech's filings show?
These are Fortress Biotech's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
How much revenue did FBIO have in 2025?
Fortress Biotech had revenue of $63M and net income of $6.8M in fiscal 2025, a net margin of 10.8%.
How much debt does FBIO have?
On December 31, 2025 Fortress Biotech had total assets of $186M, debt of $52M and shareholders' equity of $50M.
Where are the figures from?
From Fortress Biotech, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.